Key Takeaway: The article discusses multi-year subgroup analyses of participants with Niemann-Pick disease type C who were treated with arimoclomol as part of the US early access program. These findings were presented at the 22nd Annual WORLD Symposium. The ongoing research reflects a commitment to exploring treatment options for this rare disease.
Price reaction · baseline $9.16 (2026-02-03T19:59:00.000Z) · hit during market hours · clean, no other ZVRA news in the window
day 0 close · peak
0%
Market Sentiment Analysis
POSITIVE FACTORS
Multi-year analyses indicate ongoing research progress.
Arimoclomol is being evaluated for Niemann-Pick disease type C.
The study highlights participant involvement in an early access program.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Publications and Presentations
Multi-year subgroup analyses of Niemann-Pick disease type C participantstreated with arimoclomol in the US early access program (EAP)
22nd Annual WORLDSymposium - 02/03/2026
Download PDF
Download PDF
Frequently Asked Questions
What is the focus of the subgroup analyses?
The analyses focus on participants with Niemann-Pick disease type C treated with arimoclomol.
Where were the findings presented?
The findings were presented at the 22nd Annual WORLD Symposium.
What is arimoclomol used for?
Arimoclomol is being evaluated as a treatment for Niemann-Pick disease type C.
What program is associated with this study?
The study is part of the US early access program for treatment.